| 21.71 -0.31 (-1.41%) | 05-08 09:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 27.9 |
1-year : | 32.59 |
| Resists | First : | 23.88 |
Second : | 27.9 |
| Pivot price | 20.44 |
|||
| Supports | First : | 20.37 |
Second : | 18.2 |
| MAs | MA(5) : | 20.71 |
MA(20) : | 20.8 |
| MA(100) : | 23.17 |
MA(250) : | 31.88 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 75 |
D(3) : | 56.3 |
| RSI | RSI(14): 52.7 |
|||
| 52-week | High : | 58.38 | Low : | 11.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKRO ] has closed below upper band by 6.4%. Bollinger Bands are 39.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.28 - 22.39 | 22.39 - 22.49 |
| Low: | 21.23 - 21.36 | 21.36 - 21.49 |
| Close: | 21.77 - 21.98 | 21.98 - 22.2 |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Wed, 08 May 2024
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics - GlobeNewswire
Wed, 08 May 2024
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference - Yahoo Finance
Tue, 07 May 2024
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL - GlobeNewswire
Tue, 07 May 2024
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before ... - PR Newswire
Tue, 07 May 2024
AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against ... - GlobeNewswire
Tue, 07 May 2024
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 92.3 (%) |
| Shares Short | 8,180 (K) |
| Shares Short P.Month | 9,470 (K) |
| EPS | -2.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -35.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -145 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -7.62 |
| PEG Ratio | 0.3 |
| Price to Book value | 2.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|